Cost Plus Drugs Beats Health Insurance for High-Cost Generics
Chart of the Day: Mark Cuban's Cost Plus Drugs Can Save Employer-Covered Patients Hundreds on Some Generics
Search Results
Medicare’s Hidden Fix for High Drug Costs
Medicare’s Payment Plan Can Ease Seniors’ Crushing Drug Costs but Medicare Buries it in the Fine Print
Six Insights on Health Care Affordability From Penn LDI
LDI Fellows’ Research Quantifies the Effects of High Health Care Costs for Consumers and Shines Light on Several Drivers of High U.S. Health Care Costs
Patients Face New Barriers for GLP-1 Drugs Like Wegovy and Ozempic
Even With Lower Prices, Medicare, Medicaid, and Other Insurers Tighten Coverage for Drugs Like Mounjaro and Zepbound Using Prior Authorization and Other Tools
How One Study Helped Save Free Preventive Care in a Supreme Court Showdown
A 2024 Study Showing How Even Small Copays Reduce PrEP Use Fueled Media, Legal, and Advocacy Efforts As Courts Weighed a Case Threatening No-Cost Preventive Care for Millions
Black Older Adults With Cancer Are Far Less Likely to Get Any Care
New Study From LDI and MD Anderson Finds That Black and Low-Income, Dually Eligible Medicare Patients Are Among the Most Neglected in Cancer Care
In The Media Newswise
New Medicare Program Could Dramatically Improve Affordability For Cancer Drugs — If Patients Enroll
Interview
Penn LDI Small Grants Program 2025 Projects Announced
14 LDI Fellows Get Early-Stage Funding for a Range of Health Care Research Projects
A Federal Court Ruling Puts Free Preventive Care at Risk
The Braidwood Case Opens the Door For Others To Block PrEP and other Preventive Services
People With HIV on Medicare Have Surprisingly Large Gaps in Treatment
Over a Quarter had a 30-day Gap or Longer in Antiretroviral Treatment and 10% had Continuous Gaps of 90 Days or More, LDI Fellows Find